Comparative 2-year outcomes of conventional and accelerated corneal collagen crosslinking in progressive keratoconus  

作　　者：Omür O.Ucakhan Yagmur Seda Yesiltas 

机构地区：[1]Department of Ophthalmology,Ankara University Faculty of Medicine,Ankara 06550,Turkey

出　　处：《International Journal of Ophthalmology(English edition)》2020年第8期1223-1230,共8页国际眼科杂志（英文版）

摘　　要：AIM:To compare the safety and efficacy of conventional versus accelerated(9 mW/cm^2)corneal collagen crosslinking(CXL)in progressive keratoconus at the 2-year follow-up.METHODS:In this prospective study,consecutive progressive keratoconus patients were randomized to receive either conventional CXL(CCXL)or accelerated CXL(ACXL;using hydroxypropyl methylcellulose-assisted riboflavin imbibition for 10 min at 9 mW/cm^2).Visual,refractive,keratometric,topographic,and aberrometric outcomes and stromal demarcation line depth(DLD)measurements were compared at the end of a 2-year follow-up.RESULTS:Thirty-two eyes from 32 patients in the CCXL and 27 eyes from 27 patients in the ACXL groups completed 2-year follow-up.At 2y post-CXL,both uncorrected and corrected visual acuities improved significantly in both groups.The improvements in keratometric readings,flattening rate(flattening of the maximum keratometry more than 1 D),3 topographic indices,and vertical coma were significantly better in the CCXL group compared to the ACXL group(P<0.05).The DLD as measured by anterior segment optical coherence tomography or in vivo confocal microscopy was better detectable and significantly deeper in the CCXL group compared to the ACXL group.The deeper DLD was found to be significantly correlated with improvements in the mean keratometry measurements.Progression was noted in 11.1%of eyes in the ACXL group,whereas progression was not observed in any patient eye in the CCXL group.CONCLUSION:In this prospective randomized study,ACXL is less effective in halting the progression of keratoconus at a 2-year follow-up compared to CCXL.

关 键 词：corneal collagen crosslinking KERATOCONUS corneal ectasia RIBOFLAVIN accelerated crosslinking 

分 类 号：R772.2[医药卫生—眼科]